<DOC>
	<DOCNO>NCT02506140</DOCNO>
	<brief_summary>Ticagrelor reversible direct-acting oral antagonist P2Y12 ( Purinergic receptor P2Y , G-protein couple , 12 ) receptor adenosine diphosphate , provide faster , great , consistent P2Y12 inhibition Clopidogrel patient acute coronary syndrome , irrespective genetic variant affect Clopidogrel metabolism . It still undefined whether combination therapy Ticagrelor Aspirin effective Clopidogrel aspirin minor stroke transient ischemic attack ( TIA ) . The primary purpose PRINCE trial evaluate anti-platelet effect 3-month regimen ticagrelor initiate 180 mg load dose follow 90 mg twice/day combine aspirin 100 mg/day first 21 day versus 3-month regimen clopidogrel initiated 300 mg load dose follow 75 mg/day combine aspirin 100 mg/day first 21 day initiate within 24 hour symptom onset high-risk transient ischemic attack minor stroke .</brief_summary>
	<brief_title>Platelet Reactivity Acute Non-disabling Cerebrovascular Events</brief_title>
	<detailed_description>The PRINCE trial prospective , randomize , multi-centre , open-label , active-controlled , blinded-endpoint trial ( PROBE design concern clinical trial ) . A total approximately 952 patient ( 40years≤Age＜80years ) high-risk TIA ( define ABCD2 score ≥ 4 stenosis offend vessel ≥ 50 % ) minor ischemic stroke ( define NIHSS ≤ 3 ) , treat within 24 hour symptom onset enrol . Patients fulfil inclusion criterion none exclusion criterion randomize 1:1 two group offer informed content : 1 ) one group receive 180 mg load dose ticagrelor day randomization , follow 90 mg twice/day ticagrelor Day 2 3 month ; 2 ) group receive 300 mg load dose clopidogrel day randomization , follow 75 mg once/day clopidogrel Day 2 3 month . Aspirin give total dose 100-300 mg first day , follow 100 mg once/day Day 2 Day 21 group . The primary objective ass anti-platelet effect Ticagrelor combine Aspirin versus Clopidogrel combine Aspirin Chinese patient high-risk TIA minor stroke . The study consist six visit include day randomization , 2 hour first anti-platelet agent , 24 hour first anti-platelet agent , Day 7+2days , Day 21±2days Day 90±7days . Genomic DNA patient collect genotyped . And genetic variant affect Clopidogrel metabolism analyze . The antiplatelet effect analyze total subject genetic variant carrier . The trial anticipate complete 18 month first subject recruitment , 952 subject recruit 25 centre China . A Data Safety Monitoring Board ( DSMB ) regularly monitor safety study . The trial approve IRB ( Institutional Review Board ) /EC ( Ethics Committee ) Beijing Tiantan hospital , Capital Medical University .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Provision informed consent . 2 . Female male aged≥ 40 year ＜80 year . 3 . Acute nondisabling ischemic stroke ( NIHSS≤ 3 time randomization ) treat study drug within 24 hour symptom onset define '' last see normal '' principle . 4 . TIA ( Neurological deficit attribute focal brain ischemia , resolution deficit within 24 hour symptom onset ) , treat study drug within 24 hour symptom onset moderatetohigh risk stroke recurrence ( ABCD2 score ≥ 4 time randomization stenosis offend vessel ≥ 50 % ) . 1 . Diagnosis hemorrhage pathology , vascular malformation , tumor , abscess major nonischemic brain disease ( e.g. , multiple sclerosis ) baseline head Computed Tomography ( CT ) magnetic resonance imaging ( MRI ) . 2 . Isolated pure sensory symptom ( e.g. , numbness ) , isolate visual change , isolate dizziness/vertigo without evidence acute infarction baseline head CT MRI . 3 . Modified Rankin Scale Score &gt; 2 randomization ( premorbid historical assessment ) 。 4 . Contraindication ticagrelor , clopidogrel acetylsalicylic acid : Known hypersensitivity Severe renal hepatic insufficiency Severe cardiac failure , asthma Hemostatic disorder systemic bleeding History hemostatic disorder systemic bleeding History druginduced hematologic hepatic abnormality Low white blood cell ( &lt; 2 x10^9/L ) platelet count ( &lt; 100 x10^9/L ) 5 . Clear indication anticoagulation ( presumed cardiac source embolus , e.g. , atrial fibrillation , ventricular aneurysm , prosthetic cardiac valve know , suspect endocarditis suspicion cardioembolic pathology TIA/stroke ) . 6 . Continuous use ticagrelor clopidogrel 5 day randomization 7 . Current treatment ( last dose give within 10 day randomization ) heparin therapy anti coagulation therapy ( e.g. , warfarin ; thrombin inhibitor dabigatran , argatroban , bivalirudin , ximelagatran ; factor Xa inhibitor rivaroxaban , edoxaban , apixaban , betrixaban , tanexaban ; hirudin ; unfractionated low molecular weight heparin ) . 8 . Receipt intravenous/ intraarterial thrombolysis mechanical thrombectomy within 24 hour prior randomization . 9 . History intracranial hemorrhage cerebral artery amyloidosis . 10 . History aneurysm ( include intracranial aneurysm peripheral aneurysm ) 11 . Diagnosis acute coronary syndrome . 12 . History asthma COPD ( chronic obstructive pulmonary disease ) . 13 . High risk bradyarrhythmia , sick sinus syndrome seconddegree thirddegree atrioventricular block , bradycardiarelated syncope without installed pacemaker . 14 . History uric acid nephropathy . 15 . Anticipated requirement longterm ( &gt; 7 day ) nonstudy antiplatelet drug , NSAIDs ( nonsteroidal antiinflammatory drug ) affect platelet function . 16 . History previous symptomatic nontraumatic intracerebral bleed time ( asymptomatic microbleeds qualify ) , gastrointestinal ( GI ) bleed within past 3 month , major surgery within 30 day . 17 . Qualifying TIA minor stroke induce angiography surgery . 18 . Planned likely revascularization within next 3 month . 19 . Scheduled surgery interventional treatment require study drug cessation . 20 . Severe noncardiovascular comorbidity life expectancy &lt; 3 month . 21 . Pregnancy lactation , woman childbearing age practice reliable contraception document negative pregnancy test . 22 . Currently receive investigational drug device . 23 . Participation another clinical study investigational product last 30 day . 24 . Inability patient understand and/or comply study procedure and/or followup , opinion Investigator . 25 . Hematocrit ( Hct ) &lt; 30 %</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>minor stroke</keyword>
	<keyword>transient ischemic attack</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>dual anti-platelet therapy</keyword>
	<keyword>platelet reactivity</keyword>
</DOC>